ly3375880
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 17, 2017 (NCT03343587)
Timeline
Indications
Mechanism of action
- Interleukin-33INHIBITOR
IL33 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03913260 | Phase 1 | May 1, 2019 | Eli Lilly |
| NCT03831191 | Phase 2 | Feb 12, 2019 | Eli Lilly |
| NCT03343587 | Phase 1 | Nov 17, 2017 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 2 | 2017 |
1 organizations
Page 1 / 1